A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer
Open Access
Abstract
Prostate cancer (PCa) is one of the most frequent cancer in male population. Androgen deprivation therapy is the first-line strategy for the metastatic stage of the disease, but, inevitably, PCa develops resistance to castration (CRPC), becoming incurable. In recent years, clinical trials are testing the efficacy of anti-CTLA4 on CRPC. However, this tumor seems to be resistant to immunotherapies that are very effective in other types of cancers, and, so far, only the dendritic cell vaccine sipuleucel-T has been approved. In this work, we employ a mathematical model of CRPC to determine the optimal administration protocol of ipilimumab, a particular anti-CTLA4, as single treatment or in combination with the sipuleucel-T, by considering both the effect on tumor population and the drug toxicity. To this end, we first introduce a dose-depending function of toxicity, estimated from experimental data, then we define two different optimization problems. We show the results obtained by imposing different constraints, and how these change by varying drug efficacy. Our results suggest administration of high-doses for a brief period, which is predicted to be more efficient than solutions with prolonged low-doses. The model also highlights a synergy between ipilimumab and sipuleucel-T, which leads to a better tumor control with lower doses of ipilimumab. Finally, tumor eradication is also conceivable, but it depends on patient-specific parameters.Keywords
This publication has 36 references indexed in Scilit:
- Mathematical Modeling of Tumor Growth, Drug-Resistance, Toxicity, and Optimal Therapy DesignIEEE Transactions on Biomedical Engineering, 2014
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialThe Lancet Oncology, 2012
- IpilimumabNature Reviews Drug Discovery, 2011
- Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical ModelsPLOS ONE, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Ipilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunology, Immunotherapy, 2009
- A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate CancerClinical Cancer Research, 2007
- Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy–Toxicity Mathematical ModelComputers and Biomedical Research, 2000
- Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessmentToxicology, 1995
- THE TOXICITY OF POISONS APPLIED JOINTLY1Annals of Applied Biology, 1939